BridgeBio Oncology (BBOT) director awarded 31,675 options at $7.73 strike

Rhea-AI Filing Summary

BridgeBio Oncology Therapeutics director Raymond J. Kelleher received a new stock option grant covering 31,675 shares of Common Stock. The options have an exercise price of $7.73 per share and expire on June 15, 2036, giving him the right to buy shares at that price in the future.

The award vests in full on the earlier of the first anniversary of the June 16, 2026 grant date or the next Annual Meeting of Stockholders, as long as he continues serving the company through that date. After this grant, he holds 31,675 stock options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Kelleher Raymond J.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	31,675	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 31,675 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 31,675 options Exercise price: $7.73 per share Expiration date: June 15, 2036 +1 more

4 metrics

Option grant size 31,675 options Stock Option (Right to Buy) granted on June 16, 2026

Exercise price $7.73 per share Exercise price for Common Stock under option grant

Expiration date June 15, 2036 Option expiration for 31,675-share grant

Post-grant derivative holdings 31,675 options Total stock options held directly after reported transaction

Key Terms

Stock Option (Right to Buy), vest in full, Annual Meeting of Stockholders, Common Stock

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

vest in full financial

"The shares underlying the stock option vest in full upon the earlier"

Annual Meeting of Stockholders regulatory

"the date of the next Annual Meeting of Stockholders of the Issuer"

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/18/2026 - 04:57 PM Accepted by SEC EDGAR 06/18/2026 - 04:56 PM Learn about SEC filing dates

FAQ

What did BridgeBio Oncology Therapeutics (BBOT) director Raymond Kelleher report in this Form 4?

He reported receiving a stock option grant for 31,675 shares. The options give him the right to buy BridgeBio Oncology Therapeutics Common Stock at $7.73 per share, expiring on June 15, 2036, subject to the award’s vesting conditions and his continued service.

How many BridgeBio Oncology Therapeutics (BBOT) options did Raymond Kelleher receive?

He received 31,675 stock options. Each option represents the right to acquire one share of BridgeBio Oncology Therapeutics Common Stock. Following this grant, his reported derivative holdings consist of 31,675 options, with no additional derivative positions shown in this filing.

What is the exercise price of Raymond Kelleher’s BBOT stock options?

The exercise price is $7.73 per share. This means Kelleher can buy BridgeBio Oncology Therapeutics Common Stock at $7.73 if and when the options are vested and exercised, regardless of the future market price at that time.

When do Raymond Kelleher’s BridgeBio Oncology Therapeutics (BBOT) options expire?

The options expire on June 15, 2036. After that date, any unexercised options become worthless. This long-dated expiration gives Kelleher a multi-year window to potentially exercise the options once they vest.

What are the vesting terms for Raymond Kelleher’s BBOT option grant?

The options vest in full on the earlier of two dates. Vesting occurs on the first anniversary of the grant or the next Annual Meeting of Stockholders, whichever comes first, provided Kelleher continues to serve BridgeBio Oncology Therapeutics through that vesting date.

Does this BBOT Form 4 show a stock purchase or sale by Raymond Kelleher?

No, it shows a compensatory stock option grant. The reported transaction is a grant or award of 31,675 stock options, not an open-market buy or sell of existing BridgeBio Oncology Therapeutics shares, and no sale proceeds are disclosed.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kelleher Raymond J.

(Last) (First) (Middle)

BRIDGEBIO ONCOLOGY THERAPEUTICS, INC.

256 EAST GRAND AVENUE, SUITE 104

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Oncology Therapeutics, Inc. [ BBOT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$7.73	06/16/2026		A		31,675		(1)	06/15/2036	Common Stock	31,675	$0	31,675	D

Explanation of Responses:

1. The shares underlying the stock option vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting of Stockholders of the Issuer following the date of grant, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date.

	/s/ Raymond J. Kelleher	06/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)